The beta
adrenoceptor
beta agonist
clenbuterol
hypertrophy
salbutamol
thermogenesis
Journal
The Journal of physiology
ISSN: 1469-7793
Titre abrégé: J Physiol
Pays: England
ID NLM: 0266262
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
30
04
2021
accepted:
12
10
2021
pubmed:
23
10
2021
medline:
3
5
2022
entrez:
22
10
2021
Statut:
ppublish
Résumé
Treatment of obesity with repurposed or novel drugs is an expanding research field. One approach is to target beta
Substances chimiques
Adrenergic beta-2 Receptor Agonists
0
Adrenergic beta-Agonists
0
Receptors, Adrenergic, beta-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1209-1227Informations de copyright
© 2021 The Authors. The Journal of Physiology © 2021 The Physiological Society.
Références
Acheson KJ, Ravussin E, Schoeller DA, Christin L, Bourquin L, Baertschi P, Danforth E Jr. & Jequier E (1988). Two-week stimulation or blockade of the sympathetic nervous system in man: influence on body weight, body composition, and twenty four-hour energy expenditure. Metabolism 37, 91-98.
Akin BL, Hurley TD, Chen Z & Jones LR (2013). The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum. J Biol Chem 288, 30181-30191.
Amoroso P, Wilson SR, Moxham J & Ponte J (1993). Acute effects of inhaled salbutamol on the metabolic rate of normal subjects. Thorax 48, 882-885.
Andersson DC, Betzenhauser MJ, Reiken S, Umanskaya A, Shiomi T & Marks AR (2012). Stress-induced increase in skeletal muscle force requires protein kinase A phosphorylation of the ryanodine receptor. J Physiol 590, 6381-6387.
Arch JR (2011). Challenges in beta(3)-adrenoceptor agonist drug development. Ther Adv Endocrinol Metab 2, 59-64.
Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C & Wilson S (1984). Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309, 163-165.
Arlettaz A, Le Panse B, Portier H, Lecoq AM, Thomasson R, De Ceaurriz J & Collomp K (2009). Salbutamol intake and substrate oxidation during submaximal exercise. Eur J Appl Physiol 105, 207-213.
Arner P, Hellstrom L, Wahrenberg H & Bronnegard M (1990). Beta-adrenoceptor expression in human fat cells from different regions. J Clin Invest 86, 1595-1600.
Aschar-Sobbi R, Emmett TL, Kargacin GJ & Kargacin ME (2012). Phospholamban phosphorylation increases the passive calcium leak from cardiac sarcoplasmic reticulum. Pflugers Arch 464, 295-305.
Astrup A (1995). The sympathetic nervous system as a target for intervention in obesity. Int J Obes Relat Metab Disord 19(Suppl 7), S24-S28.
Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB & Fihn SD (2003). Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunctiona. Chest 123, 1964-1969.
Baker JG (2010). The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol 160, 1048-1061.
Baker PK, Dalrymple RH, Ingle DL & Ricks CA (1984). Use of a β-adrenergic agonist to alter muscle and fat deposition in lambs. J Anim Sci 59, 1256-1261.
Bakker AJ, Head SI, Wareham AC & Stephenson DG (1998). Effect of clenbuterol on sarcoplasmic reticulum function in single skinned mammalian skeletal muscle fibers. Am J Physiol 274, C1718-C1726.
Beloka SP, Janssen C, Woff E, Brassine E, Deboeck G, Randria J, Philippart de Foy V, van de Borne P & Naeije R (2011). Effects of beta2-adrenergic stimulation on exercise capacity in normal subjects. Eur J Appl Physiol 111, 2239-2247.
Bendotti C, Borsini F & Samanin R (1983). Studies on the mechanisms of tolerance to the anorectic effect of salbutamol in rats. Eur J Pharmacol 92, 237-242.
Benson DW, Foley-Nelson T, Chance WT, Zhang F-S, James JH & Fischer JE (1991). Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 50, 1-5.
Bessesen DH & Van Gaal LF (2018). Progress and challenges in anti-obesity pharmacotherapy. The Lancet Diabetes & Endocrinology 6, 237-248.
Blondin DP, Nielsen S, Kuipers EN, Severinsen MC, Jensen VH, Miard S, Jespersen NZ, Kooijman S, Boon MR, Fortin M, Phoenix S, Frisch F, Guerin B, Turcotte EE, Haman F, Richard D, Picard F, Rensen PCN, Scheele C & Carpentier AC (2020). Human brown adipocyte thermogenesis is driven by beta2-AR stimulation. Cell Metab 32, 287-300. e287.
Bluher M (2019). Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 15, 288-298.
Borsini F, Bendotti C, Thurlby P & Samanin R (1982). Evidence that systemically administered salbutamol reduces food intake in rats by acting on central beta-adrenergic sites. Life Sci 30, 905-911.
Bray GA & Wadden TA (2015). Improving long-term weight loss maintenance: can we do it? Obesity 23, 2-3.
Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC & Stinson EB (1982). Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 307, 205-211.
Brockway JM, MacRae JC & Williams PE (1987). Side effects of clenbuterol as a repartitioning agent. Vet Rec 120, 381-383.
Burniston JG, Tan LB & Goldspink DF (2006). Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats. Exp Physiol 91, 1041-1049.
Cameron RB, Peterson YK, Beeson CC & Schnellmann RG (2017). Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol. Sci Rep 7, 10578.
Cannon B & Nedergaard J (2004). Brown adipose tissue: function and physiological significance. Physiol Rev 84, 277-359.
Caruso JF, Hamill JL & De Garmo N (2005). Oral albuterol dosing during the latter stages of a resistance exercise program. J Strength Cond Res 19, 102-107.
Centner TJ, Alvey JC & Stelzleni AM (2014). Beta agonists in livestock feed: status, health concerns, and international trade. J Anim Sci 92, 4234-4240.
Choo JJ, Horan MA, Little RA & Rothwell NJ (1992). Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. American Journal of Physiology-Endocrinology and Metabolism 263, E50-E56.
Chou YC, Tsai CN, Lee YS & Pei JS (2012). Association of adrenergic receptor gene polymorphisms with adolescent obesity in Taiwan. Pediatr Int 54, 111-116.
Choudhary AS & Robinson GM (2009). Can β agonists cause dilated cardiomyopathy? Heart, Lung and Circulation 18, 367-369.
Clausen T & Nielsen OB (2007). Potassium, Na+,K+-pumps and fatigue in rat muscle. J Physiol 584, 295-304.
Cohen P, Levy Julia D, Zhang Y, Frontini A, Kolodin Dmitriy P, Svensson Katrin J, Lo James C, Zeng X, Ye L, Khandekar Melin J, Wu J, Gunawardana Subhadra C, Banks Alexander S, Camporez João Paulo G, Jurczak Michael J, Kajimura S, Piston David W, Mathis D, Cinti S, Shulman Gerald I, Seale P & Spiegelman Bruce M (2014). Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 156, 304-316.
Collins S & Surwit RS (2001). The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis. Recent Prog Horm Res 56, 309-328.
Cousin B, Cinti S, Morroni M, Raimbault S, Ricquier D, Penicaud L & Casteilla L (1992). Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization. J Cell Sci 103(Pt 4), 931-942.
Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elia E, Kessler SH, Kahn PA, English J, Chatman K, Trauger SA, Doria A & Kolodny GM (2015). Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab 21, 33-38.
Danforth E, Jr. & Himms-Hagen JH (1997). Obesity and diabetes and the beta-3 adrenergic receptor. Eur J Endocrinol 136, 362-365.
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ & Buse JB (2018). Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41, 2669-2701.
Deng C, Paoloni-Giacobino A, Kuehne F, Boss O, Revelli JP, Moinat M, Cawthorne MA, Muzzin P & Giacobino JP (1996). Respective degree of expression of beta 1-, beta 2- and beta 3-adrenoceptors in human brown and white adipose tissues. Br J Pharmacol 118, 929-934.
Dyreborg A, Krogh N, Backer V, Rzeppa S, Hemmersbach P & Hostrup M (2016). Pharmacokinetics of oral and inhaled terbutaline after exercise in trained men. Front Pharmacol 7, 150.
Elers J, Hostrup M, Pedersen L, Henninge J, Hemmersbach P, Dalhoff K & Backer V (2012). Urine and serum concentrations of inhaled and oral terbutaline. Int J Sports Med 33, 1026-1033.
Elfellah MS, Dalling R, Kantola IM & Reid JL (1989). Beta-adrenoceptors and human skeletal muscle characterisation of receptor subtype and effect of age. Br J Clin Pharmacol 27, 31-38.
Enoksson S, Talbot M, Rife F, Tamborlane WV, Sherwin RS & Caprio S (2000). Impaired in vivo stimulation of lipolysis in adipose tissue by selective beta2-adrenergic agonist in obese adolescent girls. Diabetes 49, 2149-2153.
Eriksson P, Dahlman I, Ryden M, Hoffstedt J & Arner P (2004). Relationship between beta-2 adrenoceptor gene haplotypes and adipocyte lipolysis in women. Int J Obes Relat Metab Disord 28, 185-190.
Fortier M, Wang SP, Mauriege P, Semache M, Mfuma L, Li H, Levy E, Richard D & Mitchell GA (2004). Hormone-sensitive lipase-independent adipocyte lipolysis during beta-adrenergic stimulation, fasting, and dietary fat loading. Am J Physiol Endocrinol Metab 287, E282-E288.
Frontini A, Vitali A, Perugini J, Murano I, Romiti C, Ricquier D, Guerrieri M & Cinti S (2013). White-to-brown transdifferentiation of omental adipocytes in patients affected by pheochromocytoma. Biochim Biophys Acta 1831, 950-959.
Giantin V, Ceccon A, Enzi G, Sergi G, Perini P, Bussolotto M, Schiavon M, Casadei A, Mazzoleni F, Nardo Sartori L & Zurlo F (1995). Heart rate and metabolic response to burn injury in humans. Journal of Parenteral and Enteral Nutrition 19, 55-62.
Gregorevic P, Ryall JG, Plant DR, Sillence MN & Lynch GS (2005). Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density. Am J Physiol Heart Circ Physiol 289, H344-H349.
Grimmer NM, Gimbar RP, Bursua A & Patel M (2016). Rhabdomyolysis secondary to clenbuterol use and exercise. J Emerg Med 50, e71-e74.
Hagg A, Colgan TD, Thomson RE, Qian H, Lynch GS & Gregorevic P (2016). Using AAV vectors expressing the beta2-adrenoceptor or associated Galpha proteins to modulate skeletal muscle mass and muscle fibre size. Sci Rep 6, 23042.
Hamby PL, Stouffer JR & Smith SB (1986). Muscle metabolism and real-time ultrasound measurement of muscle and subcutaneous adipose tissue growth in lambs fed diets containing a beta-agonist1. J Anim Sci 63, 1410-1417.
Haney S & Hancox RJ (2005). Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial. Respir Res 6, 107.
Hayakawa T, Nagai Y, Kahara T, Yamashita H, Takamura T, Abe T, Nomura G & Kobayashi K (2000). Gln27Glu and Arg16Gly polymorphisms of the beta2-adrenergic receptor gene are not associated with obesity in Japanese men. Metabolism 49, 1215-1218.
Hellstrom L, Large V, Reynisdottir S, Wahrenberg H & Arner P (1999). The different effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and in females. J Intern Med 245, 253-259.
Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK & Isfort RJ (2002). Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 25, 729-734.
Hochhaus G & Möllmann H (1992). Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Int J Clin Pharmacol Ther Toxicol 30, 342-362.
Holm C (2003). Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem Soc Trans 31, 1120-1124.
Hostrup M, Jacobson GA, Jessen S & Lemminger AK (2020). Anabolic and lipolytic actions of beta2 -agonists in humans and antidoping challenges. Drug Test Anal 12, 597-609.
Hostrup M, Kalsen A, Bangsbo J, Hemmersbach P, Karlsson S & Backer V (2014a). High-dose inhaled terbutaline increases muscle strength and enhances maximal sprint performance in trained men. Eur J Appl Physiol 114, 2499-2508.
Hostrup M, Kalsen A, Onslev J, Jessen S, Haase C, Habib S, Ortenblad N, Backer V & Bangsbo J (2015). Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic beta2-adrenergic stimulation in men. J Appl Physiol (1985) 119, 475-486.
Hostrup M, Kalsen A, Ortenblad N, Juel C, Morch K, Rzeppa S, Karlsson S, Backer V & Bangsbo J (2014b). beta2-adrenergic stimulation enhances Ca2+ release and contractile properties of skeletal muscles, and counteracts exercise-induced reductions in Na+-K+-ATPase Vmax in trained men. J Physiol 592, 5445-5459.
Hostrup M, Narkowicz CK, Habib S, Nichols DS & Jacobson GA (2019). Beta2 -adrenergic ligand racemic formoterol exhibits enantioselective disposition in blood and skeletal muscle of humans, and elicits myocellular PKA signaling at therapeutic inhaled doses. Drug Test Anal 11, 1048-1056.
Hostrup M, Reitelseder S, Jessen S, Kalsen A, Nyberg M, Egelund J, Kreiberg M, Kristensen CM, Thomassen M, Pilegaard H, Backer V, Jacobson GA, Holm L & Bangsbo J (2018). Beta2 -adrenoceptor agonist salbutamol increases protein turnover rates and alters signalling in skeletal muscle after resistance exercise in young men. J Physiol 596, 4121-4139.
Hsiao TJ & Lin E (2014). Evaluation of the glutamine 27 glutamic acid polymorphism in the adrenoceptor beta2 surface gene on obesity and metabolic phenotypes in Taiwan. J Investig Med 62, 310-315.
Ip EJ, Doroudgar S, Lau B & Barnett MJ (2019). Anabolic steroid users' misuse of non-traditional prescription drugs. Research in Social and Administrative Pharmacy 15, 949-952.
Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F & Nonaka K (1999). Association of polymorphisms in the beta2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 42, 98-101.
Jacobson GA, Raidal S, Hostrup M, Calzetta L, Wood-Baker R, Farber MO, Page CP & Walters EH (2018). Long-acting beta2-agonists in asthma: enantioselective safety studies are needed. Drug Saf 41, 441-449.
Jenkins NDM, Colquhoun RJ, Tomko PM, Gradnigo T, Magrini MA, Muddle TWD, Fleming S, Ferrell M & El-Sohemy A (2018). Genetic variant in the beta2 -adrenergic receptor (Arg16Gly) influences fat-free mass, muscle strength and motor unit behaviour in young men. Exp Physiol 103, 1645-1655.
Jensen J, Brennesvik EO, Bergersen H, Oseland H, Jebens E & Brors O (2002). Quantitative determination of cell surface beta-adrenoceptors in different rat skeletal muscles. Pflugers Arch 444, 213-219.
Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, Norbury WB, Branski LK, Gauglitz GG, Mlcak RP & Herndon DN (2008). Pathophysiologic response to severe burn injury. Ann Surg 248, 387-401.
Jessen S, Onslev J, Lemminger A, Backer V, Bangsbo J & Hostrup M (2018). Hypertrophic effect of inhaled beta2 -agonist with and without concurrent exercise training: a randomized controlled trial. Scand J Med Sci Sports 28, 2114-2122.
Jessen S, Reitelseder S, Kalsen A, Kreiberg M, Onslev J, Gad A, Ortenblad N, Backer V, Holm L, Bangsbo J & Hostrup M (2021). beta2-Adrenergic agonist salbutamol augments hypertrophy in MHCIIa fibers and sprint mean power output but not muscle force during 11 weeks of resistance training in young men. J Appl Physiol (1985) 130, 617-626.
Jessen S, Solheim SA, Jacobson GA, Eibye K, Bangsbo J, Nordsborg NB & Hostrup M (2020). Beta2 -adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. Drug Test Anal 12, 610-618.
Johnson M (1995). Pharmacology of long-acting beta-agonists. Ann Allergy Asthma Immunol 75, 177-179.
Kalinovich A, Dehvari N, Aslund A, van Beek S, Halleskog C, Olsen J, Forsberg E, Zacharewicz E, Schaart G, Rinde M, Sandstrom A, Berlin R, Ostenson CG, Hoeks J & Bengtsson T (2020). Treatment with a beta-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia 63, 1603-1615.
Kalsen A, Hostrup M, Backer V & Bangsbo J (2016a). Effect of formoterol, a long-acting beta2-adrenergic agonist, on muscle strength and power output, metabolism, and fatigue during maximal sprinting in men. Am J Physiol Regul Integr Comp Physiol 310, R1312-R1321.
Kalsen A, Hostrup M, Karlsson S, Hemmersbach P, Bangsbo J & Backer V (2014). Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. J Appl Physiol (1985) 117, 1180-1187.
Kalsen A, Hostrup M, Soderlund K, Karlsson S, Backer V & Bangsbo J (2016b). Inhaled Beta2-agonist increases power output and glycolysis during sprinting in men. Med Sci Sports Exerc 48, 39-48.
Kamalakkannan G, Petrilli CM, George I, LaManca J, McLaughlin BT, Shane E, Mancini DM & Maybaum S (2008). Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J Heart Lung Transpl 27, 457-461.
Koeberl DD, Case LE, Smith EC, Walters C, Han SO, Li Y, Chen W, Hornik CP, Huffman KM, Kraus WE, Thurberg BL, Corcoran DL, Bali D, Bursac N & Kishnani PS (2018). Correction of biochemical abnormalities and improved muscle function in a phase i/ii clinical trial of clenbuterol in pompe disease. Mol Ther 26, 2304-2314.
Koziczak-Holbro M, Rigel DF, Dumotier B, Sykes DA, Tsao J, Nguyen NH, Bosch J, Jourdain M, Flotte L, Adachi Y, Kiffe M, Azria M, Fairhurst RA, Charlton SJ, Richardson BP, Lach-Trifilieff E, Glass DJ, Ullrich T & Hatakeyama S (2019). Pharmacological characterization of a novel 5-hydroxybenzothiazolone-derived beta 2-adrenoceptor agonist with functional selectivity for anabolic effects on skeletal muscle resulting in a wider cardiovascular safety window in preclinical studies. J Pharmacol Exp Ther 369, 188-199.
Lafontan M & Berlan M (1993). Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34, 1057-1091.
Lange LA, Norris JM, Langefeld CD, Nicklas BJ, Wagenknecht LE, Saad MF & Bowden DW (2005). Association of adipose tissue deposition and beta-2 adrenergic receptor variants: the IRAS family study. Int J Obes (Lond) 29, 449-457.
Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L & Arner P (1997). Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 100, 3005-3013.
Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH & Astrup A (2002). Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 76, 780-788.
Lee P, Birzniece V, Umpleby AM, Poljak A & Ho KK (2015). Formoterol, a highly beta2-selective agonist, induces gender-dimorphic whole body leucine metabolism in humans. Metabolism 64, 506-512.
Lee P, Day RO, Greenfield JR & Ho KK (2013). Formoterol, a highly beta2-selective agonist, increases energy expenditure and fat utilisation in men. Int J Obes (Lond) 37, 593-597.
Lee SH, Kwak MK, Ahn SH, Kim H, Cho YY, Suh S, Song KH, Koh JM, Kim JH & Kim BJ (2019). Change of skeletal muscle mass in patients with pheochromocytoma. J Bone Miner Metab 37, 694-702.
Leite N, Lazarotto L, Milano GE, Titski AC, Consentino CL, de Mattos F, de Andrade FA & Furtado-Alle L (2015). [Beta 2-adrenergic receptor gene association with overweight and asthma in children and adolescents and its relationship with physical fitness]. Rev Paul Pediatr 33, 381-386.
Lonnqvist F, Wahrenberg H, Hellstrom L, Reynisdottir S & Arner P (1992). Lipolytic catecholamine resistance due to decreased beta 2-adrenoceptor expression in fat cells. J Clin Invest 90, 2175-2186.
Lund J & Gillum MP (2016). Towards leanness by ‘feeding’ a novel thermogenic pathway? Trends in Endocrinology & Metabolism 27, 529-530.
Maltin CA, Delday MI, Watson JS, Heys SD, Nevison IM, Ritchie IK & Gibson PH (1993). Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond) 84, 651-654.
Martineau L, Horan MA, Rothwell NJ, & Little RA (1992). Salbutamol, a β2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci 83, 615-621.
Mauriege P, De Pergola G, Berlan M & Lafontan M (1988). Human fat cell beta-adrenergic receptors: beta-agonist-dependent lipolytic responses and characterization of beta-adrenergic binding sites on human fat cell membranes with highly selective beta 1-antagonists. J Lipid Res 29, 587-601.
McCullagh EP & Engel WJ (1942). Pheochromocytoma with hypermetabolism: report of two cases. Ann Surg 116, 61-75.
Meltzer DL & Kemp JP (1991). Beta 2-agonists: pharmacology and recent developments. J Asthma 28, 179-186.
Milano G, Chiappini S, Mattioli F, Martelli A & Schifano F (2018). β-2 agonists as misusing drugs? assessment of both clenbuterol- and salbutamol-related european medicines agency pharmacovigilance database reports. Basic Clin Pharmacol Toxicol 123, 182-187.
Miller CN, Yang JY, England E, Yin A, Baile CA & Rayalam S (2015). Isoproterenol increases uncoupling, glycolysis, and markers of beiging in mature 3t3-l1 adipocytes. PLoS One 10, e0138344.
Miller MF, Garcia DK, Coleman ME, Ekeren PA, Lunt DK, Wagner KA, Procknor M, Welsh TH, Jr. & Smith SB (1988). Adipose tissue, longissimus muscle and anterior pituitary growth and function in clenbuterol-fed heifers. J Anim Sci 66, 12-20.
Mori Y, Kim-Motoyama H, Ito Y, Katakura T, Yasuda K, Ishiyama-Shigemoto S, Yamada K, Akanuma Y, Ohashi Y, Kimura S, Yazaki Y & Kadowaki T (1999). The Gln27Glu beta2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men. Biochem Biophys Res Commun 258, 138-140.
Nagase I, Yoshida T, Kumamoto K, Umekawa T, Sakane N, Nikami H, Kawada T & Saito M (1996). Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. J Clin Invest 97, 2898-2904.
Oberkofler H, Esterbauer H, Hell E, Krempler F & Patsch W (2000). The Gln27Glu polymorphism in the beta2-adrenergic receptor gene is not associated with morbid obesity in Austrian women. Int J Obes Relat Metab Disord 24, 388-390.
Ohyama K, Nogusa Y, Shinoda K, Suzuki K, Bannai M & Kajimura S (2016). A synergistic antiobesity effect by a combination of capsinoids and cold temperature through promoting beige adipocyte biogenesis. Diabetes 65, 1410-1423.
Onslev J, Jacobson G, Narkowicz C, Backer V, Kalsen A, Kreiberg M, Jessen S, Bangsbo J & Hostrup M (2017). Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men. Eur J Appl Physiol 117, 1907-1915.
Onslev J, Jensen J, Bangsbo J, Wojtaszewski J & Hostrup M (2019). beta2-agonist induces net leg glucose uptake and free fatty acid release at rest but not during exercise in young men. J Clin Endocrinol Metab 104, 647-657.
Onslev J, Thomassen M, Wojtaszewski J, Bangsbo J & Hostrup M (2021). Beta2-adrenoceptor agonist salbutamol increases leg glucose uptake and metabolic rate but not muscle glycogen resynthesis in recovery from resistance exercise of the quadriceps in lean young men. J Clin Endocrinol Metab. Ahead of print. https://doi.org/10.1210/clinem/dgab752.
Oomen JM, van Rossum CT, Hoebee B, Saris WH & van Baak MA (2005). beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab 90, 2301-2307.
Pan SJ, Hancock J, Ding Z, Fogt D, Lee M & Ivy JL (2001). Effects of clenbuterol on insulin resistance in conscious obese Zucker rats. American Journal of Physiology-Endocrinology and Metabolism 280, E554-E561.
Petrák O, Haluzíková D, Kaválková P, Štrauch B, Rosa J, Holaj R, Brabcová Vránková A, Michalský D, Haluzík M, Zelinka T & Widimský J Jr(2013). Changes in energy metabolism in pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism 98, 1651-1658.
Phillips P, Vedig A, Jones P, Chapman M, Collins M, Edwards J, Smeaton T & Duncan B (1980). Metabolic and cardiovascular side effects of the beta 2-adrenoceptor agonists salbutamol and rimiterol. Br J Clin Pharmacol 9, 483-491.
Polidori D, Sanghvi A, Seeley RJ & Hall KD (2016). How strongly does appetite counter weight loss? quantification of the feedback control of human energy intake. Obesity 24, 2289-2295.
Porter C (2017). Quantification of UCP1 function in human brown adipose tissue. Adipocyte 6, 167-174.
Porter C (2021). Adipocyte browning in response to trauma: some important methodological considerations. Shock 56, 870-871.
Porter C, Herndon DN, Chondronikola M, Chao T, Annamalai P, Bhattarai N, Saraf MK, Capek KD, Reidy PT, Daquinag AC, Kolonin MG, Rasmussen BB, Borsheim E, Toliver-Kinsky T & Sidossis LS (2016a). Human and mouse brown adipose tissue mitochondria have comparable UCP1 function. Cell Metab 24, 246-255.
Porter C, Tompkins RG, Finnerty CC, Sidossis LS, Suman OE & Herndon DN (2016b). The metabolic stress response to burn trauma: current understanding and therapies. Lancet North Am Ed 388, 1417-1426.
Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI & Kobilka BK (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450, 383-387.
Redman LM, de Jonge L, Fang X, Gamlin B, Recker D, Greenway FL, Smith SR & Ravussin E (2007). Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. J Clin Endocrinol Metab 92, 527-531.
Reeds PJ, Hay SM, Dorward PM & Palmer RM (1988). The effect of beta-agonists and antagonists on muscle growth and body composition of young rats (Rattus sp.). Comp Biochem Physiol C 89, 337-341.
Reynisdottir S, Wahrenberg H, Carlstrom K, Rossner S & Arner P (1994). Catecholamine resistance in fat cells of women with upper-body obesity due to decreased expression of beta 2-adrenoceptors. Diabetologia 37, 428-435.
Ricks CA, Dalrymple RH, Baker PK & Ingle DL (1984). Use of a β-agonist to alter fat and muscle deposition in steers. J Anim Sci 59, 1247-1255.
Rosenbaum DM, Rasmussen SG & Kobilka BK (2009). The structure and function of G-protein-coupled receptors. Nature 459, 356-363.
Ryall JG, Church JE & Lynch GS (2010). Novel role for ss-adrenergic signalling in skeletal muscle growth, development and regeneration. Clin Exp Pharmacol Physiol 37, 397-401.
Salpeter SR, Ormiston TM & Salpeter EE (2004). Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125, 2309-2321.
Schiffelers SLH, Saris WHM, Boomsma F & van Baak MA (2001). β1- andβ 2-adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men1. The Journal of Clinical Endocrinology & Metabolism 86, 2191-2199.
Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM & Leibel RL (2017). Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev 38, 267-296.
Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scimè A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR & Spiegelman BM (2008). PRDM16 controls a brown fat/skeletal muscle switch. Nature 454, 961-967.
Shaw WN (1993). Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacol Biochem Behav 46, 653-659.
Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, Premont RT, Lichtarge O & Lefkowitz RJ (2006). β-Arrestin-dependent, G Protein-independent ERK1/2 activation by the β2 adrenergic receptor*. J Biol Chem 281, 1261-1273.
Sidossis LS, Porter C, Saraf MK, Borsheim E, Radhakrishnan RS, Chao T, Ali A, Chondronikola M, Mlcak R, Finnerty CC, Hawkins HK, Toliver-Kinsky T & Herndon DN (2015). Browning of subcutaneous white adipose tissue in humans after severe adrenergic stress. Cell Metab 22, 219-227.
Simonsen L, Bulow J, Madsen J & Christensen NJ (1992). Thermogenic response to epinephrine in the forearm and abdominal subcutaneous adipose tissue. Am J Physiol 263, E850-E855.
Simonsen L, Stallknecht B & Bulow J (1993). Contribution of skeletal muscle and adipose tissue to adrenaline-induced thermogenesis in man. Int J Obes Relat Metab Disord 17(Suppl 3), S47-S51; discussion S68.
Simonsen S & Kjekshus JK (1978). The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man. Circulation 58, 484-491.
Slack RJ, Barrett VJ, Morrison VS, Sturton RG, Emmons AJ, Ford AJ & Knowles RG (2013). In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther 344, 218-230.
Spiller HA, James KJ, Scholzen S & Borys DJ (2013). A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. Substance Abuse 34, 306-312.
Stainsby WN & Lambert CR (1979). Determination of oxygen uptake in skeletal muscle. Exerc Sport Sci Rev 7, 125-151.
Stratton JR, Pfeifer MA, Ritchie JL & Halter JB (1985). Hemodynamic effects of epinephrine: concentration-effect study in humans. J Appl Physiol (1985) 58, 1199-1206.
Sun Y, Huang J, Xiang Y, Bastepe M, Juppner H, Kobilka BK, Zhang JJ & Huang XY (2007). Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 26, 53-64.
Takenaka A, Nakamura S, Mitsunaga F, Inoue-Murayama M, Udono T & Suryobroto B (2012). Human-specific SNP in obesity genes, adrenergic receptor beta2 (ADRB2), Beta3 (ADRB3), and PPAR gamma2 (PPARG), during primate evolution. PLoS One 7, e43461.
Vergnes L, Davies GR, Lin JY, Yeh MW, Livhits MJ, Harari A, Symonds ME, Sacks HS & Reue K (2016). Adipocyte browning and higher mitochondrial function in periadrenal but not SC fat in pheochromocytoma. J Clin Endocrinol Metab 101, 4440-4448.
Vosselman MJ, van der Lans AA, Brans B, Wierts R, van Baak MA, Schrauwen P & van Marken Lichtenbelt WD (2012). Systemic beta-adrenergic stimulation of thermogenesis is not accompanied by brown adipose tissue activity in humans. Diabetes 61, 3106-3113.
Ward JK, Dow J, Dallow N, Eynott P, Milleri S & Ventresca GP (2000). Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man-no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 49, 15-22.
Watt MJ, Holmes AG, Pinnamaneni SK, Garnham AP, Steinberg GR, Kemp BE & Febbraio MA (2006). Regulation of HSL serine phosphorylation in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab 290, E500-E508.
Weyer C, Gautier JF & Danforth E (1999). Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab 25, 11-21.
Whyte KF, Addis GJ, Whitesmith R & Reid JL (1987). The mechanism of salbutamol-induced hypokalaemia. Br J Clin Pharmacol 23, 65-71.
Wijers SL, Saris WH & van Marken Lichtenbelt WD (2009). Recent advances in adaptive thermogenesis: potential implications for the treatment of obesity. Obes Rev 10, 218-226.
Williams RS, Caron MG & Daniel K (1984). Skeletal muscle beta-adrenergic receptors: variations due to fiber type and training. Am J Physiol 246, E160-E167.
Wilson SR, Amoroso P, Moxham J & Ponte J (1993). Modification of the thermogenic effect of acutely inhaled salbutamol by chronic inhalation in normal subjects. Thorax 48, 886-889.
Wolfe RR, Herndon DN, Jahoor F, Miyoshi H & Wolfe M (1987). Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 317, 403-408.
Wolfe RR, Klein S, Carraro F & Weber J-M (1990). Role of triglyceride-fatty acid cycle in controlling fat metabolism in humans during and after exercise. American Journal of Physiology-Endocrinology And Metabolism 258, E382-E389.
Zhang H, Wu J & Yu L (2014). Association of Gln27Glu and Arg16Gly polymorphisms in Beta2-adrenergic receptor gene with obesity susceptibility: a meta-analysis. PLoS One 9, e100489.
Zhang J, He Q, Liu QY, Guo W, Deng XM, Zhang WW, Hu XX & Li N (2007). Differential gene expression profile in pig adipose tissue treated with/without clenbuterol. BMC Genomics 8, 433.
Zurlo F, Larson K, Bogardus C & Ravussin E (1990). Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 86, 1423-1427.